Pre-Budget Report response - GSK comments on 'patent box'

Pre-Budget Report response - GSK comments on ‘patent box'

Issued: Thursday 10 December 2009, London UK

GlaxoSmithKline (GSK) welcomes the introduction of a new measure - the ‘patent box' - announced in the Pre-Budget Report to stimulate future investment in the UK. 

The ‘patent box' will work by applying a reduced rate of Corporation Tax of 10% to income from patents from April 2013. GSK believes this new system will significantly improve the UK's international competitiveness and encourage long-term inward investment in the UK from companies seeking to build their future high technologies and manufacturing capability.

Andrew Witty, CEO of GlaxoSmithKline said, "The patent box is exactly the sort of active, long-term and creative support that we need from the Government to ensure that the UK remains an attractive place for highly skilled sectors such as pharmaceuticals. For GSK, assuming the new regime will apply to patents currently under development it will have the immediate impact of making the UK a priority area for future investments, particularly in manufacturing."

The introduction of the patent box will enable GSK to increase its existing investment in the UK. Near-term likely investments include building a state-of-the-art biopharmaceutical manufacturing plant in the UK.  Biopharmaceuticals are medicines that are made from biotechnology (biological systems or living organisms which are modified for medical purposes).  GSK currently has six biopharmaceuticals in late-stage development for treatment of diseases such as lupus and diabetes, representing 15% of GSK's clinical pipeline.

The company is also committing new investment to its facility at Ware, Hertfordshire, to manufacture next generation respiratory medicines.  GSK has significant heritage in this area and has a leading pipeline of new treatments for asthma and COPD.

In combination, these new investments in UK manufacturing will amount to approximately £500 million and will result in new jobs in UK manufacturing. The introduction of the ‘patent box' will also benefit small businesses who supply services and facilities to sectors specialising in research and development.  For example, GSK works with more than 20,000 suppliers in the UK.

GlaxoSmithKline - one of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better and live longer.  For further information please visit www.gsk.com.
 
GlaxoSmithKline Enquiries:
 
 
 
UK Media enquiries:
 Philip Thomson
 (020) 8047 5502
 
 
 Claire Brough
 (020) 8047 5502
 
 
 Stephen Rea
 (020) 8047 5502
 
 
 Alexandra Harrison
 (020) 8047 5502
 
 
  
  
 
US Media enquiries:
 Nancy Pekarek
 (919) 483 2839
 
 
 Mary Anne Rhyne
 (919) 483 2839
 
 
 Kevin Colgan
 (919) 483 2839
 
 
 Sarah Alspach
 (919) 483 2839
 
 
 
 
 
European Analyst/Investor enquiries:
 David Mawdsley
 (020) 8047 5564
 
 
 Sally Ferguson
 (020) 8047 5543
 
 
 Gary Davies
 (020) 8047 5503
 
 
 
 
 
US Analyst/ Investor enquiries:
 Tom Curry
 (215) 751 5419
 
 
 Jen Hill Baxter
 (215) 751 7002
 

Suggested Articles

After delivering a "positive surprise" in December, Biogen is painting a fuller picture of its lupus drug.

A new CRISPR technique neutralizes SARS-CoV-2 by scrambling the virus' genetic code. It could prove useful for fighting other viruses, like influenza.

The deal, which follows a bidding war with AcelRx, gives Melinta another approved antibiotic and potentially complementary R&D expertise.